4//SEC Filing
Anacor Pharmaceuticals, Inc. 4
Accession 0001209191-15-085975
CIK 0001411158operating
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 9:01 PM ET
Size
14.5 KB
Accession
0001209191-15-085975
Insider Transaction Report
Form 4
Zane Lee
VP, Clinical Dev & Interim CMO
Transactions
- Sale
Common Stock
2015-12-15$112.06/sh−1,574$176,379→ 41,173 total - Exercise/Conversion
Stock Option (right to buy)
2015-12-15−14,000→ 27,661 totalExercise: $5.59Exp: 2022-03-13→ Common Stock (14,000 underlying) - Sale
Common Stock
2015-12-15$113.14/sh−9,430$1,066,944→ 31,743 total - Sale
Common Stock
2015-12-15$114.99/sh−100$11,499→ 28,747 total - Exercise/Conversion
Common Stock
2015-12-15$5.59/sh+14,000$78,260→ 42,747 total - Sale
Common Stock
2015-12-15$113.79/sh−2,896$329,524→ 28,847 total
Footnotes (6)
- [F1]Includes shares purchased in 2015 pursuant to the Issuer's ESPP.
- [F2]This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.55 to $112.54, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.56 to $113.55, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.56 to $114.055, inclusive.
- [F6]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was January 1, 2012.
Documents
Issuer
Anacor Pharmaceuticals, Inc.
CIK 0001411158
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001411158
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 9:01 PM ET
- Size
- 14.5 KB